Danish Biotech Weekly – Week 25

Danish Biotech Weekly with insights to listed Danish biotech companies. We keep you updated on their news flow including updates on clinical trials, acquisitions, insider trading, price targets, right issues, etc.

In the past week, several companies reported results from clinical trials including Ascendis Pharma, Expres2ion and IO Biotech. Further, Saniona continued to soar with a 40% increase making the total return year-to-date more than 250% – probably due to invetors’ huge interst in new weight loss products.

Only 4 of the 20 listed, Danish biotech companies published news the past week. 11 of the 20 companies had a positive development in their share price for the week and 8 companies have had a positive share price performance year to date. Saniona is now the best performing stock this year.

Company news the past week

Ascendis Pharma

One-Year Data from Phase 3 Trial of TransCon™ PTH in Adults with Hypoparathyroidism Presented at ENDO 2023 (Link)

Biosergen

No news the past week

Cessatech

No news the past week

CS Medica

CS MEDICA A/S Secures Future Compliance with New Medical Device Regulation through Signed Contract with Notify Body (Link)

CS MEDICA A/S Secures Trademark Approval in Canada (Link)

Curasight

No news the past week

Evaxion Biotech

No news the past week

Expres2ion

12-month durability data announced for ABNCoV2 Phase II clinical trial (Link)

Fluoguide

No news the past week

Genmab

No news the past week

Gubra

No news the past week

Initiator Pharma

No news the past week

IO Biotech

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone (Link)

Pila Pharma

No news the past week

Saniona

No news the past week

Scandion Oncology

No news the past week

SynAct Pharma

No news the past week

ViroGates

No news the past week

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

The average 1-year price target among brokers that have issued a report on the stock in the last year is USD13.67. The stock is currently trading at USD7.58.

2cureX

No news the past week

SELECTED CASES

SHARE PRICE DEVELOPMENTS

On average, the Danish biotech stocks delivered a positive share price performance last week of 1.1%. In the past week, Saniona AB continued to reach new heights with a 40% increase, although the company did not report any company-specific news. CS Medica A/S followed with a 11% increase after it got trademark approval in Canada. On the other hand, Expres2ion Biotech Holding AB fell after they announced 12-month durability data for ABNCoV2, a COVID-19 booster vaccine. Curasight A/S, Zealand Pharma A/S and Saniona AB have been the best performing stocks year-to-date after soaring 108-256% after among other things partnerships and positive recommendations from authorities paving the way for approvals. The Danish biotech stocks have done great year-to-date with a total return of 15.9%.

Read more about Curasight and Fluoguide: The unique cancer treatment of the future – Today’s investment

Overview of share price developments the past week, year-to-date and last twelve months

Disclaimer 

Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra Nyemission.dk)   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.




Investornetværk:

Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Del indlægget på sociale media eller på email. 

LinkedIn
Facebook
Twitter
Email